Hepatitis C Virus Treatment and Solid Organ Transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is a primary reason for liver transplantation.
• Untreated HCV in transplant recipients leads to near-universal allograft reinfection and potential graft failure.
• Shortage of donor organs for transplantation is a critical issue, increasing waitlist mortality.

Purpose of the Study:

• To review the impact of direct-acting antiviral (DAA) therapies on liver transplantation.
• To evaluate the use of HCV-viremic organs to expand the donor pool.
• To discuss HCV treatment strategies before and after liver transplantation.

Main Methods:

• Review of current literature on HCV treatment and liver transplantation.
• Analysis of outcomes using HCV-viremic donor organs.
• Examination of pre- and post-transplant HCV management protocols.

Main Results:

• Direct-acting antiviral agents have revolutionized HCV management in transplant candidates and recipients.
• The use of HCV-viremic organs, enabled by new therapies, significantly expands the donor pool.
• Effective HCV treatment before and after transplantation improves allograft survival.

Conclusions:

• HCV treatment advancements have transformed liver transplantation eligibility and outcomes.
• Utilizing HCV-viremic donors is a viable strategy to mitigate organ shortages.
• Comprehensive HCV management is crucial for successful liver allografting.